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1. Background and Objectives 
    The growing emphasis on patent issues and 
the financial straits of public research funds have 
gradually altered the incentives for academic 
scientists, and have forced them to face increasing 
pressure to patent [1,2]. On these grounds, an 
unignorable concern is that related to the possible 
shift of academic resources toward more 
application-oriented research [3,4], and the 
patenting of inventions with lower technological 
and economic significance [5,6,7]. Thus, many 
scholars have studied patent quality issues by 
scrutinizing their determinants and changes over 
time [8,9,10]. The typical measures of university 
patent used in the literature are generally 
external metrics e.g. number of forward citations 
[11,12]. This dissertation aims to develop a 
quantitative method that is capable of evaluating 
university patent, using novel inner metrics 
generated from the contents of the academic 
patent applications. 
    The author addressed three research 
questions in the dissertation as follows: 
    1. Whether there is difference between the 
patent quality in legal aspect of US university and 
that of Japanese university, in terms of sufficiency 
of disclosure? 
    2. Whether there is difference in patent 
quality between companies and universities from 
technological perspective? 
    3.  Whether there is difference in patent 
quality from technological perspective between US 
universities and Japanese universities ? 
With these research questions in mind, the 
objectives of this thesis are stated as follows. 
The first objective is to develop a quantitative 
method to evaluate university patent quality 
using novel indicators which is generated from 
unstructured information in the claim and 
embodiment by using text mining principles. 
    The second objective is to compare Japanese 
university patents and Japanese pharmaceutical 
company patents using the above mentioned 
method. 
    The third objective is to compare Japanese 
university patents and selected U.S. university 
patents using the above mentioned method. 
2. Methodologies 
    Two parameters have been designed for 
evaluating the patent application, as follows: 
    (1) Appliedness (APP) is defined as the extent 
of which the claims of patent applications 
encompass the outcome, from basic research to 
practical use. 
    (2) Concreteness (CON) is defined as the 
extent to which the claims are evidenced by the 
experiments in the corresponding embodiment 
part in the patent application. 
    A point table has been designed to 
quantitatively measure the APP and CON by 
counting certain keywords in the claims or in the 
embodiment part of patent applications. 
Then two assumptions are stated to build up a 
model, as follows: 
    (1) According to the definition of sufficiency of 
disclosure, patent applications located above a 
certain CON/APP-ratio threshold, named the 
grantability threshold (as shown in Fig 1), are 
more likely to fulfill the sufficiency of disclosure 
requirement and, thus, obtain the grant. 
    (2) The experiments for applied research are 
often capital-intensive and primarily funded by 
companies, meaning that universities could only 
afford a small portion of applied research, due to 
resource limitation. Thus, we could assume that a 
limitation of CON for a university patent exists 
(as shown in Fig 1), since only a limited number of 
applied-research experiments can be conducted 
within a university.  
 
Fig 1. The model 
 
 
 
 
3.Results 
    Using the above mentioned model, the author 
analyzed all Japanese universities receptor patent 
applications, all Japanese company receptor 
patent applications as well as selected U.S. 
university receptor patent applications, 
respectively. The patent applications on receptor 
protein/DNA are nice fit to our study, in that 
receptors are usually involved in similar 
development routines as clinical use. Thus, the 
scope of the claimed subject matter and protection 
have high uniformity. Grantability threshold could 
be observed from all 3 groups. Afterward the 
author compared the receptor patent applications 
from all Japanese universities and that from all 
Japanese pharmaceutical companies. The result 
suggested that the limitation of research capacity 
of universities exists. Then the author compared 
the receptor patent applications from all Japanese 
universities and that from selected US 
universities. No obvious difference could be 
observed . 
   The results are shown in Fig 2 Fig 3 and Fig 4. 
An overview of total samples is shown in Fig5. 
  
 
Fig 2. Results of JP university cases 
 
Fig 3. Results of JP Pharma cases 
 
 
Fig 4. Results of US university cases 
 
Fig 5. Overview of total samples 
 
4. Discussion and Conclusions 
To the first research question “whether there is 
difference between the patent quality of US 
university and that of Japanese university in legal 
perspective, in light of sufficiency of disclosure 
requirement?” the US universities show no 
obvious difference in patent quality in legal aspect 
in terms of average CON/APP ratio. And both 
groups have cases suspectable with the 
over-claiming and under-claiming problems, and 
the latter one shows that the higher CON/APP 
ratio is not necessarily to be more beneficial to the 
applicant. Rather a balance between claims and 
embodiment would be desired in consideration of 
grantability threshold. 
To the second research question “whether there 
is difference in patent quality from technological 
perspective between companies and universities?”, 
there is obvious difference in maximal CON 
between Japanese company receptor patents and 
Japanese university receptor patents, which 
confirms the limitation of university in applied 
research, while the average CON of Japanese 
company receptor patents is lower than that of 
Japanese university cases, indicating that 
Japanese company receptor patents have lower 
average patent quality in technological 
perspective. In contrast to over-claiming issue, the 
possible reason is that lots of Japanese company 
receptor patents with low CON/APP ratio could be 
a result from defensive patenting strategy adopted 
by companies. 
To the third research question “whether there is 
difference in patent quality from technological 
perspective between US university and Japanese 
universities?”, there is neither obvious difference 
in maximal CON between US university receptor 
patents and Japanese university receptor patents, 
suggesting no great difference in research 
limitation could detected; nor obvious difference in 
average CON between US university receptor 
patents and Japanese university receptor patents, 
indicating no obvious difference in patent quality 
in technological aspect. A detailed study on the 
embodiment provided by each group shows a 
difference in the examples for relevance to disease. 
And such difference might contribute to the 
difference in license income between US and 
Japanese university patent. 
 Based on this study, several policy implications 
could be made. Over-claiming and under-claiming 
are the two most obvious issues of Japanese 
university patenting. The government should 
provide proper training for university patenting 
activity. Due to the limitation of university 
research capacity, the collaboration between the 
universities and companies should be enhanced. 
The  university researchers should undertake not 
only the academic research, but only to find out a 
“joint point” which linked the basic research 
outcome with the practical utilization, thereafter 
it would be sensible to transfer them to an outside 
companies for further development. The 
government should encourage this kind of 
academic research and help transferring its 
outcome to the industry. 
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